These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23911704)

  • 1. Nucleosomes and neutrophil activation in sickle cell disease painful crisis.
    Schimmel M; Nur E; Biemond BJ; van Mierlo GJ; Solati S; Brandjes DP; Otten HM; Schnog JJ; Zeerleder S;
    Haematologica; 2013 Nov; 98(11):1797-803. PubMed ID: 23911704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis.
    van Montfoort ML; Stephan F; Lauw MN; Hutten BA; Van Mierlo GJ; Solati S; Middeldorp S; Meijers JC; Zeerleder S
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):147-51. PubMed ID: 23104849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis.
    Nur E; van Beers EJ; Martina S; Cuccovillo I; Otten HM; Schnog JJ; Meijers JC; Mantovani A; Brandjes DP; Bottazzi B; Biemond BJ;
    Blood Cells Mol Dis; 2011 Mar; 46(3):189-94. PubMed ID: 21256776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana.
    Antwi-Boasiako C; Campbell AD
    Vasc Health Risk Manag; 2018; 14():199-204. PubMed ID: 30233199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis.
    van Tits LJ; van Heerde WL; Landburg PP; Boderie MJ; Muskiet FA; Jacobs N; Duits AJ; Schnog JB
    Biochem Biophys Res Commun; 2009 Dec; 390(1):161-4. PubMed ID: 19799864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study.
    Hierso R; Lemonne N; Villaescusa R; Lalanne-Mistrih ML; Charlot K; Etienne-Julan M; Tressières B; Lamarre Y; Tarer V; Garnier Y; Hernandez AA; Ferracci S; Connes P; Romana M; Hardy-Dessources MD
    Br J Haematol; 2017 Mar; 176(5):805-813. PubMed ID: 27984639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Nucleosomes and Neutrophil Activation Link to Disease Progression in Patients with Scrub Typhus but Not Murine Typhus in Laos.
    Paris DH; Stephan F; Bulder I; Wouters D; van der Poll T; Newton PN; Day NP; Zeerleder S
    PLoS Negl Trop Dis; 2015; 9(8):e0003990. PubMed ID: 26317419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises.
    Barbu EA; Mendelsohn L; Samsel L; Thein SL
    Cytokine; 2020 Mar; 127():154933. PubMed ID: 31778959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vaso-occlusive crisis.
    Hounkpe BW; Chenou F; Domingos IF; Cardoso EC; Costa Sobreira MJV; Araujo AS; Lucena-Araújo AR; da Silva Neto PV; Malheiro A; Fraiji NA; Costa FF; Bezerra MAC; Santos MNN; De Paula EV
    Res Pract Thromb Haemost; 2021 Jan; 5(1):204-210. PubMed ID: 33537545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Neutrophil to Lymphocyte Ratio in Sickle Cell Disease With Vaso-Occlusive Crisis.
    Maharaj S; Chang S
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):79-82. PubMed ID: 36634279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Iron in Patients with Sickle Cell Disease Mediates the Release of Neutrophil Extracellular Traps.
    Van Avondt K; Schimmel M; Bulder I; van Mierlo G; Nur E; van Bruggen R; Biemond BJ; Luken BM; Zeerleder S
    Transfus Med Hemother; 2023 Aug; 50(4):321-329. PubMed ID: 37767280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum zinc level during and after acute painful episodes in children with sickle cell anemia at the aminu kano teaching hospital, Kano, Northern Nigeria.
    Kudirat AA; Shehu UA; Kolade E; Ibrahim M
    Niger J Clin Pract; 2019 Jan; 22(1):16-23. PubMed ID: 30666015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated circulating stromal-derived factor-1 levels in sickle cell disease.
    Landburg PP; Nur E; Maria N; Brandjes DP; Biemond BJ; Schnog JB; Duits AJ;
    Acta Haematol; 2009; 122(1):64-9. PubMed ID: 19816012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis.
    Nur E; Mairuhu W; Biemond BJ; van Zanten AP; Schnog JJ; Brandjes DP; Otten HM;
    Am J Hematol; 2010 Nov; 85(11):902-4. PubMed ID: 20882525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of circulating blood and endothelial cell microparticles in sickle-cell disease.
    Kasar M; Boğa C; Yeral M; Asma S; Kozanoglu I; Ozdogu H
    J Thromb Thrombolysis; 2014; 38(2):167-75. PubMed ID: 24254379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.
    Lamarre Y; Romana M; Waltz X; Lalanne-Mistrih ML; Tressières B; Divialle-Doumdo L; Hardy-Dessources MD; Vent-Schmidt J; Petras M; Broquere C; Maillard F; Tarer V; Etienne-Julan M; Connes P
    Haematologica; 2012 Nov; 97(11):1641-7. PubMed ID: 22689686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine profile of sickle cell disease in Oman.
    Pathare A; Al Kindi S; Alnaqdy AA; Daar S; Knox-Macaulay H; Dennison D
    Am J Hematol; 2004 Dec; 77(4):323-8. PubMed ID: 15551290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease.
    Browne PV; Mosher DF; Steinberg MH; Hebbel RP
    Am J Hematol; 1996 Apr; 51(4):296-301. PubMed ID: 8602630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.